We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Transcription Factor Inhibitors Block Growth of Lethal Brain Tumor

By LabMedica International staff writers
Posted on 10 Nov 2015
Print article
Image: MRI renderings of mouse brain tumors. Tumors treated with SKOG102 (lower panels) shrank by about half compared to tumors treated with a control (upper panels) (Photo courtesy of the University of California, San Diego).
Image: MRI renderings of mouse brain tumors. Tumors treated with SKOG102 (lower panels) shrank by about half compared to tumors treated with a control (upper panels) (Photo courtesy of the University of California, San Diego).
A new approach for treating the deadly brain tumor glioblastoma multiforme (GBM) is based on small molecule inhibitors of the major class of protein signaling molecules known as transcription factors (TFs), which are essential for tumor survival and growth.

Transcription factors are a major class of protein signaling molecules that play critical cellular roles in cancers, such as the highly lethal brain cancer GBM. Although TFs are promising targets for drug intervention, the development of specific TF inhibitors has proved difficult owing to expansive protein-protein interfaces and the absence of hydrophobic pockets.

OLIG2 is a basic helix-loop-helix (bHLH) TF that is critical in tumorigenesis and regulates the survival and expansion of GBM. It is highly expressed in all diffuse gliomas and nearly 100% of glioma cancer stem cells (CSCs) that are positive for the CD133 stem cell marker. Typically, OLIG2 is not active in normal brain tissue and it is not found in normal tissues outside the central nervous system (CNS). The over-expression of OLIG2 in GBM cells inhibits cellular differentiation and apoptosis as well as promotes resistance to chemotherapy and radiation therapy.

Investigators at the University of California, San Diego (USA) utilized a novel combined pharmacophore-based small molecule design methodology, to identify several candidate TF inhibitors. A number of these compounds demonstrated selective OLIG2 pathway inhibition and in vitro anti-GBM potency in biochemical, cell-based, and reporter assays.

The investigators reported in the October 30, 2015, online edition of the journal Oncotarget that the most active compound, SKOG102, was OLIG2 selective. The drug entered the brain and exhibited potent anti-GBM activity in cell-based assays and in pre-clinical mouse GBM models, where it shrank transplanted human glioblastoma tumors by an average of 50%.

"Most drugs target stable pockets within proteins, so when we started out, people thought it would be impossible to inhibit the transient interface between two transcription factors," said first author Dr. Igor Tsigelny, senior program project scientist at the University of California, San Diego. "But we addressed this challenge and created a new strategy for drug design - one that we expect many other researchers will immediately begin implementing in the development of drugs that target similar proteins, for the treatment of a variety of diseases."

SKOG102 will now undergo detailed pharmacodynamic, biophysical, and mechanistic studies in order to better understand its efficacy and possible toxicity. To this end, the compound has been licensed to the drug development company Curtana Pharmaceuticals (Austin, TX, USA), which will groom the inhibitor for clinical applications.

Related Links:
University of California, San Diego
Curtana Pharmaceuticals


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.